ACRS — Aclaris Therapeutics Share News
0.000.00%
Last trade - 00:00- $628.49m
- $523.07m
- $7.83m
U.S. STOCKS ON THE MOVE-Boeing, Booking Holdings, Eli Lilly
U.S. STOCKS ON THE MOVE-Walmart, Lyft, CrowdStrike
Aclaris hits record low after scrapping rheumatoid arthritis drug development
U.S. STOCKS ON THE MOVE-HP, Digital World Acquisition, Guardant Health
Aclaris plunges after scrapping rheumatoid arthritis drug
Aclaris Therapeutics to stop development of rheumatoid arthritis drug (updated)
Aclaris Therapeutics to stop development of rheumatoid arthritis drug
Brief: Aclaris Therapeutics To Discontinue Further Development Of ATI-450 Program
Brief: Aclaris Therapeutics Sees Cash, Cash Equivalents And Marketable Securities As Of Sep. 30 Sufficient To Fund Operations Through End Of 2025
Aclaris Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Aclaris Therapeutics Announces Positive Results From Phase 1 Trial Of Ati-2138, An Investigational Oral Covalent Itk/Jak3 Inhibitor
Aclaris Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Rio Tinto, BurgerFi International, Aclaris Therapeutics
Aclaris Therapeutics up on enrollment completion in RA treatment trial
U.S. RESEARCH ROUNDUP- Cigna Group, McKesson, Zscaler
U.S. STOCKS ON THE MOVE-Tyson Foods, Estee Lauder, Energy stocks
Brief: Aclaris Therapeutics Reports Q1 2023 Financial Results And Provides A Corporate Update
Aclaris Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Aclaris Therapeutics shares fall on wider Q1 loss